UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~August~~November 2128, 2025

BRIACELL THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

British ColumbiaA1		47-1099599
British Columbia A1		47-1099599
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1		V7T 2X1
(Address of principal executive offices)		(Zip Code)

(604) 921-1810

(Registrant’s telephone number, including area code)

Commission File No. 001-40101

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	BCTX	The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value	BCTXW	The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value	BCTXZ	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 87.01 ~~Other~~Regulation ~~Events~~FD Disclosure.

On ~~August~~November 2128, 2025, ~~BriaCell~~BriaPro Therapeutics Corp., ~~(the~~a ~~“Company”~~two-third (2/3) ~~issued~~owned asubsidiary ~~press~~of ~~release~~BriaCell ~~announcing~~Therapeutics ~~the~~Corp. ~~consolidation~~ (the “~~Consolidation~~Company”), offiled ~~the~~its ~~issued~~Consolidated ~~and~~Financial ~~outstanding~~Statements ~~common~~and ~~shares~~management’s ~~(the~~discussion ~~“Common~~and ~~Shares”)~~analysis offor the ~~Company~~period onended ~~the~~July ~~basis~~31, of2025, ~~one~~with ~~(1) post-Consolidation~~the ~~Common~~British ~~Share~~Columbia ~~for~~Securities ~~every~~Commission ~~ten~~and ~~(10)~~Alberta ~~pre-Consolidation~~Securities ~~Common~~Commission. ~~Shares~~A ~~which~~copy ~~became~~of ~~effective under~~ the ~~corporate~~Consolidated ~~law~~Financial ofStatements ~~British~~and ~~Columbia, Canada~~management’s ondiscussion ~~August~~and ~~25,~~analysis ~~2025.~~for ~~The~~the ~~post-Consolidation~~period ~~Common~~ended ~~Shares~~July ~~commenced~~31, ~~trading~~2025 onare ~~the~~included ~~Toronto~~as ~~Stock~~Exhibit ~~Exchange~~99.1 and ~~The~~Exhibit ~~Nasdaq~~99.2 ~~Capital~~to ~~Market at~~this ~~market~~Current ~~open~~Report on ~~August~~Form 8-K ~~25,~~and ~~2025,~~are ~~under~~incorporated ~~the~~herein ~~new~~by ~~CUSIP number 107930307~~reference.

The ~~press~~information ~~release~~furnished ispursuant ~~attached~~to ~~hereto~~this asItem 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference ~~herein~~into any filing of the Company under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.

Item 9.01 ~~Condensed~~Consolidated ~~interim~~Financial ~~financial~~Statements ~~statements~~ and Exhibits

Exhibit No.
99.1		Press Release dated August 21, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

EXHIBIT INDEX

Exhibit No.
99.1		BriaPro Therapeutics Corp. Consolidated Financial Statements for the period ended July 31, 2025.
99.2		BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the period ended July 31, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRIACELL THERAPEUTICS CORP.
	/s/ William V. Williams
August 25, 2025	William V. Williams
November 28, 2025	William V. Williams
	President and Chief Executive Officer

Filing Compare · BriaCell Therapeutics Corp.